Senate Bill 316 Would Hike Health Care Costs for Nevada Families, Employers, and Unions by Millions Every Year

Senate Bill 316 is a Big Pharma-backed proposal that would ban pay-for-performance incentives in the private health care marketplace—eliminating a key tool that employers and unions use to lower prescription drug costs for hardworking Nevada residents.

Instead of lowering the cost of prescription drugs, the bill undermines market-based savings, drives up insurance premiums and increases out-of-pocket costs for millions of Nevada residents who rely on employer or union-provided health coverage.

Employers and unions negotiate better deals on prescription drugs through voluntarily choosing to hire pharmacy benefit managers (PBMs), critical members of the health care system that pool their negotiating power to unlock savings for health plan sponsors, and the patients and families on these plans.

Senate Bill 316 would ban pay-for-performance incentives in the private health care marketplace that are essential for Nevada employers and unions to secure significant savings on prescription drugs, directly leading to higher premium costs for patients.

This bill is not about protecting patients—it’s about protecting Big Pharma’s profits.